Xencor (XNCR) Following XmAb819 Webcast Plans, Is The Pipeline Narrative Starting To Look Undervalued?

Simply Wall St.10-21 13:34

Xencor (XNCR) is moving back into focus after the company set an October 26 webcast to walk investors through Phase 1 data for its XmAb819 kidney cancer program and outlined a 2027 registration study....

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment